← All stories
Markets
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
EB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial Reported preclinical dat…
Covered by 1 outlet
All coverage · 1 article